London, United Kingdom

Queen Mary, University of London

www.qmul.ac.uk
London, United Kingdom

Queen Mary, University of London is a public research university located in London, United Kingdom and a constituent college of the federal University of London. With roots dating back to 1785, Queen Mary was formed by the merger of four historic colleges, and since joining the University of London in 1915 has grown to become one of its largest colleges. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Queen Mary, University of London | Date: 2017-04-19

The present invention provides an antibody which comprises a variable heavy (VH) chain comprising CDR1, CDR2 and CDR3, and/or a variable light (VL) chain comprising CDR1, CDR2 and CDR3, wherein the CDRs have the same amino acid sequence as those from a complete antibody isolated from a synovial tissue sample of rheumatoid arthritis patients, as listed in Tables 1 and 2 or Tables 1 A and 2 A.


The present invention relates to the treatment of trauma haemorrhage or trauma haemorrhage-induced organ injury and associated disorders (in particular stoke, burns and brain injury) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the treatment of myocardial infarction and coronary heart disease (and associated disorders) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the use of artemisinin and its derivatives in coronary artery bypass surgery, heart transplantation, and diseases associated with ischaemia-reperfusion.


Patent
Queen Mary, University of London | Date: 2017-05-24

The present invention relates to a method for treating and/or preventing a disease associated with protein aggregation which comprises the step of preventing protein aggregation associated with RNA removal, by stabilising RNA; or reversing protein aggregation associated with RNA removal, by effectively replacing removed RNA.


Patent
Regenerate, Barts Health Nhs Trust and Queen Mary, University of London | Date: 2017-04-19

The present invention provides a composition comprising cells obtainable by bone marrow aspiration, or multipotent or pluripotent progenitor cells,and granulocyte-colony stimulating factor (G-CSF), as a combined preparation for simultaneous, separate or sequential use in the therapy of cardiomyopathy in a subject, wherein the cells are administered directly to the myocardium of the subject.


Patent
Queen Mary, University of London | Date: 2017-01-04

The presence of certain auto-antibodies and miRNAs indicates that a subject has endometriosis. The auto-antibodies recognise antigens listed in Table 1. The miRNAs are also listed in Table 1.


Patent
Queen Mary, University of London | Date: 2017-05-24

The present invention provides a method for determining whether a Rheumatoid Arthritis (RA) patient is susceptible to treatment with a B cell targeted therapy, which method comprises the step of analysing B cells and/or germinal centre-like structures (GC-LS) in a synovial tissue sample from the patient; wherein a patient whose synovial tissue sample is B cell rich and/or GC-LS negative is determined to be susceptible to treatment with the B cell targeted therapy, whereas a patient whose synovial tissue sample is B-cell poor and/or GC-LS positive is determined to be resistant to treatment with the B cell targeted therapy.


Patent
Queen Mary, University of London | Date: 2015-06-12

The present invention provides an antibody which comprises a variable heavy (VH) chain comprising CDR1, CDR2 and CDR3, and/or a variable light (VL) chain comprising CDR1, CDR2 and CDR3, wherein the CDRs have the same amino acid sequence as those from a complete antibody isolated from a synovial tissue sample of rheumatoid arthritis patients, as listed in Tables 1 and 2 or Tables 1 A and 2 A.


Patent
Regenerate, Barts Health Nhs Trust and Queen Mary, University of London | Date: 2015-06-10

The present invention provides a composition comprising cells obtainable by bone marrow aspiration, or multipotent or pluripotent progenitor cells, and granulocyte-colony stimulating factor (G-CSF), as a combined preparation for simultaneous, separate or sequential use in the therapy of cardiomyopathy in a subject, wherein the cells are administered directly to the myocardium of the subject.


Patent
German Cancer Research Center and Queen Mary, University of London | Date: 2016-12-21

The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods.


Patent
Queen Mary, University of London | Date: 2017-02-08

The present invention relates to an oncolytic vaccinia virus and virus vectors for use in cancer therapy where in the virus comprises at least three vaccinia virus promoters which are positioned in the same orientation.

Loading Queen Mary, University of London collaborators
Loading Queen Mary, University of London collaborators